NCT05805397 Effectiveness of Motivation Skills Training (MST)
| NCT ID | NCT05805397 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-04-15 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will take place at four outpatient clinics serving adults with serious mental illness. Informed consent will be obtained from N=80 individuals with a Diagnostic and Statistical Manual of Mental Illnesses (DSM)-5 diagnosis of schizophrenia or schizoaffective disorder meeting inclusion/exclusion criteria to participate in a randomized controlled trial comparing Motivation Skills Training (MST) to a Healthy Behaviors Control (HBC) group. Eligible participants will receive a baseline assessment including sociodemographic and psychosocial assessments, measures of motivation, goal attainment, and quality of life, as well as measures of executive skills, community functioning, and psychiatric symptoms severity. Both MST and HBC will be implemented as once weekly group therapies. The treatment phase is approximately 12-14 weeks. MST will focus on motivation knowledge and self-regulation skills while HBC will focus on physical health and health-related skills.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-65 2. DSM-5 Diagnosis of Schizophrenia or Schizoaffective Disorder 3. Medically and psychiatrically stable outpatient status 4. English Fluency Exclusion Criteria: 1. Indications of Intellectual Disability as documented in medical history or measured by \< 70 premorbid full scale Intelligence Quotient (IQ) estimate 2. Severe substance use within the past three months determined by DSM-5 criteria 3. Neurologic condition causing brain disease 4. Mild to severe cognitive impairment associated with possible dementia measured by a Mini Mental Status Exam score below 20 in individuals ages 60 and older
Contact & Investigator
Alice Saperstein, PhD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT05805397 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05805397 currently recruiting?
Yes, NCT05805397 is actively recruiting participants. Contact the research team at Alice.Saperstein@nyspi.columbia.edu for enrollment information.
Where is the NCT05805397 trial being conducted?
This trial is being conducted at New York, United States, New York, United States.
Who is sponsoring the NCT05805397 clinical trial?
NCT05805397 is sponsored by Columbia University. The principal investigator is Alice Saperstein, PhD at Columbia University. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.